The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne

This study is currently recruiting participants.

Verified by Shaheed Beheshti Medical University, January 2008

First Received: October 16, 2006 Last Updated: January 22, 2008 History of Changes

Sponsor:	Shaheed Beheshti Medical University
Information provided by:	Shaheed Beheshti Medical University
ClinicalTrials.gov Identifier:	NCT00388778

Purpose

The purpose of this study is to compare the safety and efficacy of twice daily subantimicrobial dose doxycycline 20mg with daily doxycycline 100mg in treatment of mild and moderate Acne.

Condition	Intervention	Phase
Acne Inflammation	Drug: Doxycycline	Phase II Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Official Title:	The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne

Resource links provided by NLM:

MedlinePlus related topics: Acne

Drug Information available for: Doxycycline Doxycycline hyclate Doxycycline calcium

U.S. FDA Resources

Further study details as provided by Shaheed Beheshti Medical University:

Estimated Enrollment:	100
Study Start Date:	October 2005
Estimated Study Completion Date:	October 2006

Eligibility

Ages Eligible for Study:	18 Years to 40 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Acne

Exclusion Criteria:

Pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00388778

Contacts

Contact: Parviz Toossi, M.D.

98-21-22744392

src@sbmu.ac.ir

Locations

Iran, Islamic Republic of
Skin Research Center, Shaheed Beheshti Medical University	Recruiting
Tehran, Iran, Islamic Republic of, 19899
Contact: Parviz Toossi, M.D. 98-21-22744392 src@sbmu.ac.ir
Principal Investigator: Parviz Toossi, M.D.
Sub-Investigator: Nahid Mohtasham, MD

Sponsors and Collaborators

Shaheed Beheshti Medical University

Investigators

Principal Investigator:

Parviz Toossi, M.D.

Shaheed Beheshti Medical University

More Information

No publications provided

Study ID Numbers:	src-pts-964
Study First Received:	October 16, 2006
Last Updated:	January 22, 2008
ClinicalTrials.gov Identifier:	NCT00388778 History of Changes
Health Authority:	Iran: Ethics Committee

Additional relevant MeSH terms:

Anti-Infective Agents
Antiprotozoal Agents
Facial Dermatoses
Skin Diseases
Sebaceous Gland Diseases
Acne Vulgaris
Pharmacologic Actions
Inflammation

Anti-Bacterial Agents
Antimalarials
Antiparasitic Agents
Pathologic Processes
Acneiform Eruptions
Therapeutic Uses
Doxycycline

ClinicalTrials.gov processed this record on November 25, 2009